Development of microfluidic angiogenesis assay for drug testing and companion diagnostics

用于药物测试和伴随诊断的微流体血管生成测定的开发

• 批准号: 500666-2016
• 负责人: Young, EdmondWaiKeung
• 金额: $ 1.82万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=608227
• 关键词: Development; microfluidic; angiogenesis; assay; drug

Armour Therapeutics Inc. is a biopharmaceutical company based in Toronto, Ontario that has developed a candidate drug for advanced prostate cancer (PCa), the most common type of cancer among men in Canada and in the developed world. The candidate drug, AT-001, offers the potential for patients to continue hormone therapy even beyond the point where tumours become insensitive to traditional anti-hormone therapies. While Armour Therapeutics has made progress to bring AT-001 to the clinic, key questions related to the effects of AT-001 on blood vessel growth, or angiogenesis, remain unanswered. Furthermore, drug regulatory bodies are increasingly favouring the development of complementary diagnostic tests, termed companion diagnostic

Armour Therapeutics Inc.是一家位于安大略省多伦多的生物制药公司，该公司开发了一种用于晚期前列腺癌（PCa）的候选药物，前列腺癌是加拿大和发达国家男性中最常见的癌症类型。候选药物AT-001为患者提供了继续激素治疗的潜力，甚至超过了肿瘤对传统抗激素治疗不敏感的程度。虽然Armour Therapeutics在将AT-001用于临床方面取得了进展，但AT-001对血管生长或血管生成的影响的关键问题仍未得到解答。此外，药物监管机构越来越倾向于开发补充性诊断测试，称为伴随诊断